1
|
Hennequin C, Belkacémi Y, Bourgier C, Cowen D, Cutuli B, Fourquet A, Hannoun-Lévi JM, Pasquier D, Racadot S, Rivera S. Radiotherapy of breast cancer. Cancer Radiother 2021; 26:221-230. [PMID: 34955414 DOI: 10.1016/j.canrad.2021.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Adjuvant radiotherapy is an essential component of the treatment of breast cancer. After conservative surgery for an infiltrating carcinoma, radiotherapy must be systematically performed, regardless of the characteristics of the disease, because it decreases the rate of local recurrence and by this way, specific mortality. A boost dose over the tumour bed is required if the patient is younger than 50 years-old. Partial breast irradiation could be routinely proposed as an alternative to whole breast irradiation, but only in selected and informed patients. For ductal carcinoma in situ, adjuvant radiotherapy must be also systematically performed after lumpectomy. After mastectomy, chest wall irradiation is required for pT3-T4 tumours and if there is an axillary nodal involvement, whatever the number of involved lymph nodes. After neoadjuvant chemotherapy and mastectomy, in case of pN0 disease, chest wall irradiation is recommended if there is a clinically or radiologically T3-T4 or node positive disease before chemotherapy. Axillary irradiation is recommended only if there is no axillary surgical dissection and a positive sentinel lymph node. Supra- and infraclavicular irradiation is advised in case of positive axillary nodes. Internal mammary irradiation must be discussed case by case, according to the benefit/risk ratio (cardiac toxicity). Hypofractionation regimens (42.5Gy in 16 fractions, or 41,6Gy en 13 or 40Gy en 15) are equivalent to conventional irradiation and must prescribe after tumorectomy in selected patients. Delineation of the breast, the chest wall and the nodal areas are based on clinical and radiological evaluations. 3D-conformal irradiation is the recommended technique, intensity-modulated radiotherapy must be proposed only in specific clinical situations. Respiratory gating could be useful to decrease the cardiac dose. Concomitant administration of chemotherapy in unadvised, but hormonal treatment could be start with or after radiotherapy.
Collapse
Affiliation(s)
- C Hennequin
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - Y Belkacémi
- Hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - C Bourgier
- Institut du cancer Montpellier (ICM), 34000 Montpellier, France
| | - D Cowen
- Hôpital La Timone, AP-HM, 13000 Marseille, France
| | - B Cutuli
- Polyclinique Courlancy, 51000 Reims, France
| | - A Fourquet
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - J-M Hannoun-Lévi
- Centre Antoine-Lacassagne, 33, avenue Valombrose, 06000 Nice, France
| | - D Pasquier
- Centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France
| | - S Racadot
- Centre Léon-Bérard, 69000 Lyon, France
| | - S Rivera
- Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| |
Collapse
|
2
|
Bourgier C, Cowen D, Lemanski C, Castan F, Rivera S, De La Lande B, Peignaux K, Le Blanc-Onfroy M, Benyoucef A, Mege A, Douadi-Gaci Z, Racadot S, Latorzeff I, Schick U, Jacquot S, Massabeau C, Guilbert P, Geffrelot J, Ellis S, Lecouillard I, Breton-Callu C, Richard-Tallet A, Bontemps P, Fenoglietto P, Azria D. OC-0594 Acute toxicity results after breast-conserving therapy in “boost vs no boost (BONBIS)” DCIS trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31014-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Fryer S, Stone K, Dickson T, Wilhelmsen A, Cowen D, Faulkner J, Lambrick D, Stoner L. The effects of 4 weeks normobaric hypoxia training on microvascular responses in the forearm flexor. J Sports Sci 2018; 37:1235-1241. [PMID: 30558476 DOI: 10.1080/02640414.2018.1554177] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Intermittent exposure to hypoxia can lead to improved endurance performance. Currently, it is unclear whether peripheral adaptions play a role in improving oxygen delivery and utilization following both training and detraining. This study aimed to characterize skeletal muscle blood flow (mBF), oxygen consumption (mV̇O2), and perfusion adaptations to i) 4-weeks handgrip training in hypoxic and normoxic conditions, and ii) following 4-weeks detraining. Using a randomised crossover design, 9 males completed 30-min handgrip training four times a week in hypoxic (14% FiO2 ~ 3250m altitude) and normoxic conditions. mBF, mV̇O2 and perfusion were assessed pre, post 4-weeks training, and following 4-weeks detraining. Hierarchical linear modelling found that mV̇O2 increased at a significantly faster rate (58%) with hypoxic training (0.09 mlO2·min-1 · 100g-1 per week); perfusion increased at a significantly (69%) faster rate with hypoxic training (3.72 μM per week). mBF did not significantly change for the normoxic condition, but there was a significant increase of 0.38 ml· min-1 · 100ml-1 per week (95% CI: 0.35, 0.40) for the hypoxic condition. During 4-weeks detraining, mV̇O2 and perfusion significantly declined at similar rates for both conditions, whereas mBF decreased significantly faster following hypoxic training. Four weeks hypoxic training increases the delivery and utilisation of oxygen in the periphery.
Collapse
Affiliation(s)
- S Fryer
- a School of Sport and Exercise , University of Gloucestershire , Gloucester , UK
| | - K Stone
- a School of Sport and Exercise , University of Gloucestershire , Gloucester , UK
| | - T Dickson
- a School of Sport and Exercise , University of Gloucestershire , Gloucester , UK
| | - A Wilhelmsen
- b School of Life Sciences, Metabolic and Molecular Physiology Research Group , University of Nottingham , UK
| | - D Cowen
- a School of Sport and Exercise , University of Gloucestershire , Gloucester , UK
| | - J Faulkner
- c Faculty of Business, Law and Sport , University of Winchester , Winchester , UK
| | - D Lambrick
- d Faculty of Health Sciences , University of Southampton , Southampton , UK
| | - L Stoner
- e Department of Sport and Exercise , University of North Carolina , Chapel Hill , NC , USA
| |
Collapse
|
4
|
Nirrengarten M, Nomikossof N, Garnier E, Cowen D. 22 State of the art and breast cancer treatments in Tomotherapy. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.09.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
5
|
Calderon B, Guerder C, Resbeut M, Fakhry N, Dupuis C, Cowen D. [Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers]. Cancer Radiother 2016; 20:83-90. [PMID: 26969244 DOI: 10.1016/j.canrad.2015.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Revised: 09/07/2015] [Accepted: 10/14/2015] [Indexed: 10/22/2022]
Abstract
PURPOSE Retrospectively evaluate the safety, feasibility and efficacy of concomitant chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers. PATIENTS AND METHODS Patients' data from three radiotherapy centres in South of France, with locally advanced head and neck cancers, and treated between December 2007 and July 2013 by concomitant chemoradiotherapy, after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil, were analysed. Adverse effects were graduated according to CTCAE v3.0 criteria. Overall survival and disease-free survival were calculated according to Kaplan-Meier method. RESULTS One hundred and sixty-eight patients, mostly oropharynx (38%) T4 (46%) N2 (54%) tumors, received, after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil, a concomitant chemoradiotherapy with platin or cetuximab, which delivered 66 to 70Gy. Grade 3-4 adverse effects were less frequent in the group of patients who received cisplatin (with or withour 5-fluoro-uracil) at 100mg/m(2) each 21 days compared to cetuximab (radiomucositis: 32.5% vs 61%, P=0.018; radioepithelitis: 13% vs 61 %, P<0.0001). Chemopotentiation was incomplete for 21% of patients without impacting survival. Two years overall survival and disease-free survival were respectively of 81% and 64%. Lymph nodes status and WHO status significantly influenced these survivals (overall survival 84% if N<3 vs 56% if N3, P=0.017 and 85 % if WHO status ≤ 1 vs 50% if WHO status>1, P=0.006; disease-free survival 66% if N<3 vs 47% if N3, P=0.046). CONCLUSION The association of induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil and concomitant chemoradiotherapy shows satisfying results with an acceptable toxicity. The terms of the chemopotentiation and its superiority to a single concomitant chemoradiotherapy treatment still remain to be clarified.
Collapse
Affiliation(s)
- B Calderon
- Service de radiothérapie, centre hospitalier universitaire de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France.
| | - C Guerder
- Centre de radiothérapie Saint-Louis, Croix-Rouge française, quartier Sainte-Musse, rue André-Blondel, 83100 Toulon, France
| | - M Resbeut
- Service de radiothérapie, institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 9, France
| | - N Fakhry
- Service de chirurgie ORL, centre hospitalier universitaire de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France
| | - C Dupuis
- Service d'oncologie médicale, centre hospitalier universitaire de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France
| | - D Cowen
- Service de radiothérapie, centre hospitalier universitaire de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France; Faculté de médecine de Marseille, 27, boulevard Jean-Moulin, 13005 Marseille, France
| |
Collapse
|
6
|
Branger N, Padovani L, Rossi D, Thirion X, Coulange C, Cowen D, Lechevallier E, Muracciole X. Une hormonothérapie adjuvante d’une durée de 1 an est elle suffisante chez les patients de plus de 65ans avec un cancer de prostate à haut risque traité par radio-hormonothérapie ? Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Zaccariotto A, Tallet A, Maingon P, Lemanski C, Guerder C, Teissier E, Bourgier C, Conte M, Cowen D. Triple Negative Breast Cancer: Which Factors Predict for Local Recurrence? A Study of the CORS Group. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Moureau-Zabotto L, Ortholan C, Hannoun-Lévi JM, Tessier E, Cowen D, Salem N, Lemanski C, Ellis S, Resbeut M. Influence du boost en curiethérapie dans la prise en charge des cancers du canal anal avec envahissement ganglionnaire initial (étude CORS-03). Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Dubergé T, Bénézery K, Resbeut M, Azria D, Minsat M, Ellis S, Teissier E, Zaccariotto A, Champetier C, Cowen D. [Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases]. Cancer Radiother 2012; 16:247-56. [PMID: 22652299 DOI: 10.1016/j.canrad.2012.02.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Revised: 02/20/2012] [Accepted: 02/27/2012] [Indexed: 10/28/2022]
Abstract
PURPOSE Adenoid cystic carcinoma represents 1% of head and neck cancers. Adenoid cystic carcinomas are slow growing tumours with high potential for local recurrence. Treatment usually associates radiotherapy and surgery, but the role of radiotherapy remains unclear. We report a retrospective multicentric study of the management and prognostic factors of 169 adenoid cystic carcinomas of head and neck. PATIENTS AND METHODS Between 1982 and 2010, 169 patients with adenoid cystic carcinoma of the head and neck were referred to the Cercle des oncologues radiothérapeutes du Sud departments of radiotherapy either for primary untreated tumour (n=135) or for a recurrence of previously treated tumour (n=34). The site of adenoid cystic carcinoma was: parotid gland (n=48, 28.4%), minor salivary gland (n=35, 20.7%), submandibular gland (n=22, 13%), sinus cavities (n=22, 13%), other (n=42, 24.9%). Tumour stages were: T1 (12.4%); T2 (14.2%); T3 (12.4%); T4 (41.4%) and Tx (19.5%). Lymph node involvement was 13% and distant metastasis 8.9%. For adenoid cystic carcinomas of the parotid gland, major nerve involvement was evaluated. Preferential site of metastasis was the lung (87.5%). Treatments were: surgery alone (n=27), surgery and adjuvant radiotherapy (n=89), surgery and adjuvant chemoradiotherapy (n=12), exclusive chemoradiotherapy (n=13), exclusive radiotherapy (n=14), other associations (n=5) and no treatment (n=7). Radiotherapy was delivered through photons (n=119), neutrons (n=6), both (n=4). Two patients had a brachytherapy boost. Median prescribed doses to T and N were respectively 65 Gy and 50 Gy for the 119 photons treated patients. RESULTS Mean follow-up was 58 months (range 1-250 months). As of December 1, 2010, 83 patients were alive with no evolutive disease (49%), 35 alive and had recurred, 18 had uncontrolled evolutive disease, 28 had died of adenoid cystic carcinoma and 5 of intercurrent disease. Overall survival and disease free survival were respectively 72% and 72% at 5 years, 53% and 32% at 10 years; 5 and 10-year freedom from local recurrence were 81% and 52% respectively. Nerve involvement was found in 17/48 parotid gland adenoid cystic carcinomas. The Cox model including all patients, showed that surgery (P<0.001), surgical margins (P=0.015), nerve involvement (P=0.0079), length of radiotherapy (P=0.018), and tumour location (P=0.041) were associated with disease free survival. CONCLUSION In this large series of adenoid cystic carcinoma of head and neck with a majority of T3-T4 tumours, 10-year survivals were achieved for 50% of patients. Radiotherapy did not impact survival.
Collapse
Affiliation(s)
- T Dubergé
- Service de radiothérapie, hôpital de la Timone adultes, Marseille, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Padovani L, Taright N, Muraracciole X, Nomikossof N, Capdeville S, Portal T, Cowen D. Comparaison dosimétrique entre l’irradiation conformationelle et la tomothérapie hélicoïdale dans la maladie de Hodgkin sus-diaphragmatique en pédiatrie. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Cowen D, Duberger T, Hannoun-Levi J, Azria D, Salem N, Ellis S, Teissier E, Resbeut M. Adenoid Cystic Carcinoma Of The Head and Neck: Retrospective Series Of 169 Cases. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Birns J, Cowen D, Walport M, Walport S. Julius Cowen. West J Med 2011. [DOI: 10.1136/bmj.d5636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Acklam P, Bedingfield P, Cunningham F, Cowen D, McConkey G, Fishwick C, Johnson P, Parsons M. X-ray crystallographic studies of rationally designed dihydroorotate dehydrogenase inhibitors. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311092178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
14
|
Azria D, Cowen D, Bourgier C, de la Lande B, Gourgou-Bourgade S, Douadi Gaci Z, Leblanc-Onfroy M, Latorzeff I, Pradier O, Maingon P, Lecouillard I, Bontemps P, Ellis S, Levy C, Benyoucef A, Racadot S, Laharie-Mineur H, Lagarde P, Marchal C, Lemanski C. Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Champetier C, Hannoun-Levi JM, Resbeut M, Azria D, Salem N, Tessier E, Ellis S, Cowen D. Radiothérapie postopératoire dans les sarcomes utérins : étude rétrospective multicentrique. Cancer Radiother 2011; 15:89-96. [DOI: 10.1016/j.canrad.2010.05.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2009] [Revised: 05/04/2010] [Accepted: 05/11/2010] [Indexed: 11/29/2022]
|
16
|
Serin D, Clippe S, Resbeut M, Radji A, Jovenin N, Benoit C, Spaeth D, Puyuelo L, Jaubert D, Cowen D, Ferrero JM, Marty M, Buyse M, El Amiri H, Piedbois P. Abstract P5-11-06: Impact of Educational Material on Compliance and Persistence Rates with Adjuvant Aromatase Inhibitors: First Year Data in Patients Recruited in France (CARIATIDE STUDY). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-11-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rationale: Issues have been reported with aromatase inhibitors (AI) compliance in adjuvant breast cancer. The present study was performed in order to better assess patient (pt) compliance, and to test whether educational material (EM) can improve compliance rate. Methods: This 2-year observational study (NCT00681122) was conducted on 2,758 patients in 18 countries, and completed in March 2009. Pts were allocated to Standard Therapy AI (anastrozole or letrozole), Group A, or to Standard Therapy + EM (Group B) following a 1:1 randomisation. EM consisted of a range of information on breast cancer-related topics. Primary endpoint was compliance rate for AI: patient is defined as being compliant if she took more than 80% of her tablets during the last year. Secondary endpoints were: persistence rate at 1 and 2 years (patient is classified as a persistent user of adjuvant AI medication when the data supports the persistent intake of adjuvant AI medication during the one-year period), and reasons for and time to AI discontinuation. Specialised questionnaires were used to evaluate pt compliance and behaviour (EORTC-INPATSAT-32, OPTIMA-X, GHQ-12, FACT-ES, compliance questionnaire and EM feedback in Group B).Results: 711 pts were randomised in France, 348 in Groupe A and 363 in Groupe B. Pt characteristics were well balanced across randomised arms. Mean age was 65 years, mean BMI was 26, 20% of pts had received hormone replacement therapy, and 68% had associated co-morbidities, including musculoskeletal disorders in 12%. Preliminary analysis showed that compliance rate at 1 year was only 74%, with no difference between the 2 groups (73% in Group A vs. 74% in Group B).
Persistence rates were also similar (77% vs.78%). AI discontinuations were mainly attributed to AI related side effects. Prognostic factor analysis showed no baseline characteristics associated with compliance behaviours.Conclusion: At 1 year, Cariatide preliminary analysis showed that compliance rate of adjuvant AI in France does not exceed 74%, and is not improved by EM.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-06.
Collapse
Affiliation(s)
- D Serin
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - S Clippe
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - M Resbeut
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - A Radji
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - N Jovenin
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - C Benoit
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - D Spaeth
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - L Puyuelo
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - D Jaubert
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - D Cowen
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - J-M Ferrero
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - M Marty
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - M Buyse
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - H El Amiri
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| | - P. Piedbois
- Institut Sainte Catherine and Association Européenne de Recherche en Oncologie (AERO), Avignon, France; Centre Marie Curie, Valence, France; Centre de Radiothérapie Saint-Louis, Toulon, France; Centre Frédéric Joliot, Rouen, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre d'Oncologie de Gentilly, Nancy, France; Nouvelle Clinique de l'Union, Saint Jean, France; Clinique Tivoli, Bordeaux, France; Hôpital Timone, Marseille, France; Centre Antoine Lacassagne, Nice, France; Hôpital Saint Louis, Paris, France; IDDI, Brussels, Belgium; AstraZeneca, Rueil-Malmaison, France
| |
Collapse
|
17
|
Dubergé T, Padovani L, Zaccariotto A, Gross E, Champetier C, Cowen D. Métastases pulmonaires : intérêt, limites et place de la radiothérapie par rapport aux autres modalités thérapeutiques. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Gross E, Hannoun-Levi JM, Rouanet P, Houvenaeghel G, Teissier E, Ellis S, Resbeut M, Tallet A, Vaini Cowen V, Azria D, Cowen D. [Evaluation of immediate breast reconstruction and radiotherapy: factors associated with complications]. Cancer Radiother 2010; 14:704-10. [PMID: 20674442 DOI: 10.1016/j.canrad.2010.05.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2009] [Revised: 05/01/2010] [Accepted: 05/12/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVES To determine prospectively the factors associated with reconstruction failure (i.e. requiring expander removal) and capsular contracture in patients undergoing mastectomy and immediate two-stage breast reconstruction with a tissue expander and implant, and radiotherapy for breast cancer. This is a multi-institutional prospective nonrandomized trial. PATIENTS AND METHODS Between 2/1998 and 9/2006, we prospectively evaluated 141 consecutive patients who received 141 implants after mastectomy and underwent chest wall radiotherapy (46 to 50 Gy in 23 to 25 fractions). Patients were evaluated after 24 to 36 months by two senior physicians (radiation oncologist and surgeon). RESULTS Medical follow-up was 37 months. Baker 1 and 2 capsular contracture was observed in 67.5% of patients, Baker 3 and 4 in 32.5%. There were 32 reconstruction failures. In a univariate analysis, the following factors were associated with Baker 3 and 4 capsular contracture: surgeon, use of hormonotherapy and smoking, of which only one remained in the multivariate analysis: surgeon. In a univariate analysis, the following factors were associated with reconstruction failure: tumor size T3 or T4, smoking, pN+ axilla. Three factors remained associated with reconstruction failure in a multiple logistic regression: large tumors T3/T4, smoking and pN+ axilla. CONCLUSIONS Mastectomy, radiotherapy and immediate breast reconstruction with a tissue expander and implant should be considered when breast conserving surgery has been denied. Adequate patients can be easily selected by using three factors of favourable outcome.
Collapse
Affiliation(s)
- E Gross
- Département de radiothérapie, hôpital de la Timone, rue Saint-Pierre, 13005 Marseille, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wolf A, Cowen D, Paige B. HUMAN TOXOPLASMOSIS: OCCURRENCE IN INFANTS AS AN ENCEPHALOMYELITIS VERIFICATION BY TRANSMISSION TO ANIMALS. Science 2010; 89:226-7. [PMID: 17737029 DOI: 10.1126/science.89.2306.226] [Citation(s) in RCA: 119] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Wolf A, Cowen D, Paige BH. TOXOPLASMIC ENCEPHALOMYELITIS : IV. EXPERIMENTAL TRANSMISSION OF THE INFECTION TO ANIMALS FROM A HUMAN INFANT. ACTA ACUST UNITED AC 2010; 71:187-214. [PMID: 19870956 PMCID: PMC2135077 DOI: 10.1084/jem.71.2.187] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
1. Infected material from the brain and spinal cord of an infant suffering from a recently recognized form of granulomatous encephalomyelitis was inoculated into rabbits and mice and produced an experimental disease which was readily transmissible in series. 2. A parasite identical with that in the lesions of the human case was found in the lesions of the experimental animals. 3. The morphology of this microorganism, the course of the disease and the lesions produced in the animals inoculated with it, the wide host range of this parasite, and the results of cross immunity experiments, establish its identity as a Toxoplasma. It is suggested that the microorganism be designated Toxoplasma hominis. 4. The clinical and pathologic features of the infection produced in animals by this Toxoplasma are described. 5. The infection in the infant is the first proved instance of human toxoplasmosis. Since the lesions were confined to the central nervous system the disease is termed toxoplasmic encephalomyelitis. 6. The first experimental transmission of human toxoplasmosis to animals is recorded.
Collapse
Affiliation(s)
- A Wolf
- Neuropathology Department of the College of Physicians and Surgeons, Columbia University, the Neuropathology Department of the Neurological Institute, and the Department of Pathology of the Babies Hospital, New York
| | | | | |
Collapse
|
21
|
Padovani L, Leseur J, André N, Figarella-Branger D, Lena G, Frappaz D, Gentet J, Carrie C, Cowen D, Muracciole X. Pediatric Medulloblastoma: Educational Long-term Outcome and Clinical Factors. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Cowen D, Spiro M. Bernard Perlow. West J Med 2009. [DOI: 10.1136/bmj.b3310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Gross E, George L, Cowen D, Cazalet M, Pignon T. A dose-volume histogram analysis of the PTV in patients with advanced head and neck cancer treated with concomitant chemoradiotherapy. Radiother Oncol 2007. [DOI: 10.1016/s0167-8140(07)80122-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Georae L, Gross E, Digue L, Cowen D, Zanaret M, Pignon T. Late toxicity of concomitant radiotherapy and chemotherapy in head and neck cancer. Radiother Oncol 2007. [DOI: 10.1016/s0167-8140(07)80061-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
25
|
Padovani L, Lechevallier E, Bastide C, Badinand D, Rossi D, Thirion X, Coulange C, Cowen D, Muracciole X. 2296. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Muracciole X, Cowen D, Régis J. [Radiosurgery and brain radio-induced carcinogenesis: update]. Neurochirurgie 2004; 50:414-20. [PMID: 15179297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The use of radiosurgery Gamma-knife for many benign tumors and diseases has increased significantly over the last two decades. The long-term potential carcinogenic risk has not been evaluated until recently. The definition of radio-induced tumors was based on Cahan's criteria: it must occur in the previously irradiated field, with a sufficiently long interval from irradiation, it must be pathologically different from the primary tumor, not be present at time of irradiation and no genetic predisposition for second tumor. The brain is one of most sensitive tIssues and no minimal dose has been established. Even doses as low as 1 Gy have been associated with second tumor formation and relative risk between 1.57 and 8.75. This relative risk increases to 18.4 for an interval time between 20 and 25 Years. Many publications emphaze the risks after larger-field, fractionated radiotherapy with low non-cell-killing dose delivered to central nervous system. Furthermore, therapeutic radiation doses for benign tumors associated with a long life (parasellar tumors, meningioma) were implicated in carcinogenesis. Incidence of radiation-associated tumors is linked to different factors such as age and individual genetic susceptibility. At this time and to our knowledge, 3 radiation-associated gliomas and 5 malignant acoustic neurinomas have been reported in the literature. Moreover, these second tumors met some but not all Cahan criteria. We also report 2 cases from our radiosurgical experience and discuss these points. Long time follow-up is needed to observe the crude incidence of radiation-induced tumors at 5 to 30 Years. The relative risk is estimated less than 1 and must be announced to each patient before the radiosurgical procedure and counterbalanced wit the 1% annual risk of mortality from bleeding of untreated MAV or the 1% mortality rate of benign tumors after surgery alone.
Collapse
Affiliation(s)
- X Muracciole
- Service de Radiothérapie, Hôpital Universitaire de La Timone, Marseille
| | | | | |
Collapse
|
27
|
Beckendorf V, Bachaud JM, Bey P, Bourdin S, Carrie C, Chapet O, Cowen D, Guérif S, Hay HM, Lagrange JL, Maingon P, Le Prisé E, Pommier P, Simon JM. [Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials]. Cancer Radiother 2002; 6 Suppl 1:78s-92s. [PMID: 12587386 DOI: 10.1016/s1278-3218(02)00217-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The delineation of target volume and organs at risk depends on the organs definition, and on the modalities for the CT-scan acquisition. Inter-observer variability in the delineation may be large, especially when patient's anatomy is unusual. During the two french multicentric studies of conformal radiotherapy for localized prostate cancer, it was made an effort to harmonize the delineation of the target volumes and organs at risk. Two cases were proposed for delineation during two workshops. In the first case, the mean prostate volume was 46.5 mL (extreme: 31.7-61.3), the mean prostate and seminal vesicles volume was 74.7 mL (extreme: 59.6-80.3), the rectal and bladder walls varied respectively in proportion from 1 to 1.45 and from 1 to 1.16; in the second case, the mean prostate volume was 53.1 mL (extreme: 40.8-73.1), the volume of prostate plus seminal vesicles was 65.1 mL (extreme: 53.2-89), the rectal wall varied proportionally from 1 to 1, 24 and the vesical wall varied from 1 to 1.67. For participating centers to the french studies of dose escalation, a quality control of contours was performed to decrease the inter-observer variability. The ways to reduce the discrepancies of volumes delineation, between different observers, are discussed. A better quality of the CT images, use of urethral opacification, and consensual definition of clinical target volumes and organs at risk may contribute to that improvement.
Collapse
Affiliation(s)
- V Beckendorf
- Radiothérapie, centre Alexis-Vautrin, 54511 Vandoeuvre-lès-Nancy, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Bey P, Beckendorf V, Carrie C, Aletti P, Ginestet C, Madelis G, Pommier P, Cowen D, Gonzague-Casabianca L, Simonian-Sauve M. Definitive results of a phase II escalating dose multicentric study in prostate adenocarcinoma from 66 Gy up to 80 Gy. Int J Radiat Oncol Biol Phys 2001. [DOI: 10.1016/s0360-3016(01)02349-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
29
|
Alzieu C, Hannoun-Levi J, Ellis S, Tessier E, Houvenaeghel G, Bautrant E, Resbeut M, Cowen D. Second conservative treatments for local recurrences in breast cancer: feasibility and results. Int J Radiat Oncol Biol Phys 2001. [DOI: 10.1016/s0360-3016(01)01838-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
McDonnell T, Cowen D, Troncoso P, Zagars G, von Eschenbach A, Meistrich M, Pollack A. Molecular markers of patient outcome in prostate cancer treated with radiotherapy: Ki-67, Bcl-2, Bax, and Bcl-x. Int J Radiat Oncol Biol Phys 2001. [DOI: 10.1016/s0360-3016(01)02030-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Resbeut MR, Alzieu C, Gonzague-Casabianca L, Badinand D, Bardou VJ, Cravello L, Gamerre M, Houvenaeghel G, Cowen D. Combined brachytherapy and surgery for early carcinoma of the uterine cervix: analysis of extent of surgery on outcome. Int J Radiat Oncol Biol Phys 2001; 50:873-81. [PMID: 11429214 DOI: 10.1016/s0360-3016(01)01602-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE The aim of this retrospective study was to evaluate the survival data and rates and patterns of complications and recurrences for patients who had early uterine cervix carcinoma and underwent brachytherapy and subsequent surgery. METHODS AND MATERIALS Between January 1990 and December 1997, 192 women with cervical carcinoma (Stages IA2 with vascular invasion [n = 28], IB1 [n = 144], and IIA [n = 20]) underwent brachytherapy, delivering 60 Gy and then hysterectomy with external iliac lymphadenectomy. Piver class I, II, and III hysterectomies were performed on 136, 38, and 18 patients, respectively. Adjuvant chemoradiotherapy was delivered to patients with positive lymph nodes. RESULTS The median follow-up time was 61 months. After brachytherapy, a pathologically complete response (CR) was observed in 137 (71.3%) of 192 women. The distribution of CRs according to tumor stage was as follows: Stage IA2, 24 (85.7%) of 28; Stage IB1, 105 (72.9%) of 144; and Stage IIA, 8 (40%) of 20. Patients with Stage IB1 cancer had 13 lymph node metastases (9%), as did 6 with Stage IIA disease (30%). Pelvic recurrences occurred in 9 (4.6%) of the 192 patients; in 3, local relapses were associated with relapses at distant sites. Ten patients had systemic relapses (5.2%). Recurrences at distant sites were more frequent (p < 0.02) in partial responders, and other recurrences were more frequent in patients with lymph node metastases (p < 0.04). The overall 5-year disease-free survival rate was 91.2% (96.2% for Stage IA2, 91% for Stage IB1, and 84.4% for Stage IIA cancers). The class of hysterectomy did not influence the outcome. Late complications occurred in 28 patients (Grade 1, 24 [12.5%]; Grade 2, 4 [2%]; and Grade 3, 1 [0.5%] of 192 patients). CONCLUSIONS Combined treatments resulted in high local control and low morbidity rates in patients with early-stage cervical carcinoma. Limited surgery seemed to be adequate after intracavitary therapy.
Collapse
Affiliation(s)
- M R Resbeut
- Department of Radiation Oncology, Institut Paoli-Calmettes Cancer Center, Marseille, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Beckendorf V, Pommier P, Carrie C, Bey P, Cowen D, Gonzague-Casabianca L, Maingon P, Horiot JC, Lagrange JL, Madelis G, Luporsi E. [Multicenter study on dose escalation with conformal and conventional radiotherapy for the treatment of localized prostatic cancer. Preliminary results of tolerance and quality of life]. Prog Urol 2001; 11:264-76. [PMID: 11400488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
OBJECTIVE To study the safety of conformal radiotherapy dose escalation up to 80 Gy for curative treatment of prostate cancer. MATERIAL AND METHODS A multicentre trial sponsored by the PHRC include 164 patients under the age of 75 years with stage T1b-T3 N0 M0 prostatic adenocarcinoma, between 1995 and 1998. The prostate was treated at 5 dose levels: 18 patients at 66 Gy, 28 at 70 Gy, 49 at 74 Gy, 48 at 78 Gy, 21 at 80 Gy. The acute and delayed toxicity was graded according to a multidisciplinary glossary. Quality of life was evaluated before and one year after treatment using the EORTC QLQ-C30 questionnaire and additional questions. RESULTS 89% and 55% of mild or moderate gastrointestinal and urinary adverse effects were observed during treatment, respectively. At long-term follow-up, of the 162 evaluable patients, 12.3% presented grade 2 adverse effects and 2.5% presented grade 3 adverse effects (1 case of haematuria, 2 urethral strictures, 1 bladder neck lesion) with no significant difference between the various dose levels. Two successive quality of life questionnaires were available for 119 patients: tiredness, pain and dyspnoea increased in parallel, but non-significantly in the groups receiving conventional doses or high doses. The proportion of patients reporting sexual activity without endocrine therapy decreased from 48% before treatment to 35% one year later. The proportion of patients with no clinical or laboratory signs of progression was higher in the high-dose group. CONCLUSION No significant difference was observed between conventional dose levels and high dose levels in terms of toxicity or quality of life. As the adverse effects were acceptable, a randomized trial comparing 70 Gy and 80 Gy has been initiated.
Collapse
Affiliation(s)
- V Beckendorf
- Département de Radiothérapie, Centre Alexis Vautrin, 54511 Vandoeuvre lès Nancy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys 2000; 48:1507-12. [PMID: 11121656 DOI: 10.1016/s0360-3016(00)01409-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE/OBJECTIVE The effect of adenoviral-mediated p53 transgene expression on the radiation response of two human prostate cancer cell lines, the p53(wild-type) LNCaP and p53(null) PC3 lines, was examined. The objective was to determine if this vector sensitizes cells to radiation independently of their p53 status. METHODS AND MATERIALS A recombinant adenovirus-5 vector (RPR/INGN 201, Introgen Therapeutics, Houston, TX) containing a CMV promoter and wild-type p53-cDNA (Ad5-p53) was used to facilitate p53 transgene expression. A multiplicity of infection (MOI) of 10-40 viral particles per cell was used, based on Ad5/CMV/lacz infection and staining for the beta-galactosidase reporter gene product. Clonogenic assays were performed to evaluate the degree of sensitization to radiation of viral-transduced cells compared with irradiated nontransduced controls. The relative efficacy of these treatments to induce apoptotic cell death was determined using the TUNEL assay. RESULTS The delivery of Ad5-p53 (10 MOI) reduced control plating efficiency from 36.5% to 0.86% in the LNCaP cell line and from 75.1% to 4.1% in the PC3 cell line. After correcting for the effect of Ad5-p53 on plating efficiency, the surviving fraction after 2 Gy (SF2) of gamma-irradiation was reduced over 2.5-fold, from 0.187 to 0.072, with transgene p53 expression in the LNCaP cell line. Surviving fraction after 4 Gy (SF4) was reduced over 4.5-fold, from 0.014 to 0.003, after Ad5-p53 treatment. In the PC3 cell line, Ad5-p53 (40 MOI) reduced SF2 over 1.9-fold from 0.708 to 0.367, and SF4 over 6-fold from 0.335 to 0.056. In both the LNCaP and PC3 cell lines, the combination of Ad5-p53 plus radiation (2 Gy) resulted in supra-additive apoptosis (approximately 20% for LNCaP and approximately 15% for PC3 at 50 MOI), above that seen from the addition of the controls; control vector Ad5-pA plus RT (0.15% for LNCaP and 1.44% for PC3), Ad5-p53 alone (28.6% for LNCaP and 21.7% for PC3), RT alone (0% for LNCaP and 0.23% for PC3), or Ad5-pA alone (0.1% for LNCaP and 0.29% for PC3). CONCLUSION The clonogenic survival and apoptosis data demonstrate that p53 transgene expression sensitizes human prostate adenocarcinoma cells in vitro to irradiation. As this effect was observed in both the p53(wild-type) LNCaP and p53(null) PC3 lines, radiosensitization was independent of p53 status.
Collapse
Affiliation(s)
- P J Colletier
- Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
| | | | | | | | | | | | | |
Collapse
|
34
|
Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, Pollack A. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res 2000; 6:4402-8. [PMID: 11106260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
An adenovirus 5 vector containing wild-type p53 cDNA (Ad5-p53) and a cytomegalovirus promoter was used to generate p53 transgene expression. Control vector (Ad5-pA) contained the poly-adenosine sequence. PC3 cells (2 x 10(6)) were injected s.c. into the legs of nude mice. Treatment with Ad5-p53 was initiated at a tumor volume of 200 mm3. Three intratumoral injections (days 1, 4, and 7) were given with 3 x 10(8) plaque-forming units, followed by 5 Gy pelvic irradiation (day 8) in one fraction using a cobalt-60 source. Tumor volume measurements were obtained every 2 days. LNCaP cells (2 x 10(6)) were injected orthotopically into the prostates of nude mice, and tumor weight was approximated using serum prostate-specific antigen (PSA) obtained from weekly tail vein bleedings. The target PSA for the start of the studies was 5 ng/ml. The intraprostatic injections of Ad5-p53 were done twice (days 1 and 2) and followed by 5 Gy pelvic irradiation on day 3. The PC3 tumor volume growth curves were log transformed and fitted using linear regression. The times (in days) for the tumors to reach 500 mm3 were calculated as 10.7 +/- 0.7 (+/- SE) for the saline control (no virus), 9.8 +/- 2.1 for Ad5-pA, 15.6 +/- 1.6 for Ad5-p53, 14.6 +/- 1.5 radiation therapy (RT; 5 Gy), 14.6 +/- 1.5 for Ad5-pA plus RT, and 31.4 +/- 5.3 for Ad5-p53 plus RT. The Ad5-p53 plus RT times were significantly different from the other groups. An enhancement factor of 3.4 was calculated, indicating supra-additivity. LNCaP tumor growth was determined via weekly serum PSA measurements. Treatment failure was determined using two PSA-based methods; a serum PSA of > 1.5 ng/ml or two rises in PSA during 6 weeks posttreatment. The results were similar using either end point. Treatment with Ad5-p53 plus 5 Gy resulted in significantly fewer PSA failures (<30%), as compared with Ad5-p53 alone (64-73%) and the other controls (approximately 80-100%) These results are also consistent with a supra-additive inhibition of tumor growth. Tumor growth in vivo was inhibited supra-additively when p53null and p53wildtype prostate tumors were treated with Ad5-p53 and 5 Gy radiation.
Collapse
Affiliation(s)
- D Cowen
- Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, Luporsi E, Pommier P, Cowen D, Gonzague-Casabianca L, Simonian-Sauve M, Maingon P, Naudy S, Lagrange J, Marcie S. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int J Radiat Oncol Biol Phys 2000; 48:513-7. [PMID: 10974470 DOI: 10.1016/s0360-3016(00)00691-x] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE To evaluate the feasibility of dose escalation in a multi-institutional study in prostate cancer patients. METHODS AND MATERIALS Between October 1995 and October 1998, 164 patients with localized adenocarcinoma of the prostate were treated with 3-dimensional conformal radiotherapy at one of five French institutions. The dose of radiation was escalated from 66 to 80 Gy (ICRU point). The maximum dose to the rectal wall was limited to 75 Gy. RESULTS Results were compared in two groups, one (group 1) receiving the standard dose (n = 46 patients; 66 to 70 Gy) and the other (group 2) receiving the escalated dose (n = 118 patients; 74 to 80 Gy). There was no difference in the characteristics of patients between the two groups. The mean follow-up time was 32 months in group 1 and 17.5 months in group 2. No statistical difference between the two groups was observed in the incidence of late gastrointestinal and urinary toxicities. The probability of achieving a posttreatment prostate-specific antigen nadir of </=1 ng/mL in the 120 patients who did not receive neoadjuvant androgen-deprivation therapy was significantly higher in the dose-escalation group and was directly related to the dose of radiation given. CONCLUSION This multi-institutional study demonstrated the feasibility of escalating the dose of radiation to 80 Gy in prostate cancer patients.
Collapse
Affiliation(s)
- P Bey
- Centre AlexisVautrin, Nancy, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Cowen D. Do not disturb. How to make sure outdoor construction doesn't disrupt operations. Health Facil Manage 2000; 13:50, 52, 54-5. [PMID: 11183993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
37
|
Mathoulin-Portier MP, Viens P, Cowen D, Bertucci F, Houvenaeghel G, Geneix J, Puig B, Bardou VJ, Jacquemier J. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin. Oncol Rep 2000; 7:675-80. [PMID: 10767389 DOI: 10.3892/or.7.3.675] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
One hundred and sixty-two breast carcinomas treated by adjuvant chemotherapy were investigated in immunohistochemistry for expression of p53 and two wild-type p53-regulated induced proteins, mdm2 and p21/waf1. p21 and mdm2 were expression stongly correlated with Ki67 but not with survival. The p53+/p21+, p53+/p21- and p53+/mdm2- phenotypes were associated with the worst prognosis. The p53+/p21+/ mdm2+ tumors were associated with a better outcome than the other phenotypes, they may be tumors expressing wild-type p53 and p21, and a form of mdm2 that might lead to the stabilization of p53. It is suggested that p21/mdm2 expression should be investigated in all cases of p53 positive breast cancer.
Collapse
|
38
|
Cowen D, Houvenaeghel G, Bardou V, Jacquemier J, Bautrant E, Conte M, Viens P, Largillier R, Puig B, Resbeut M, Maraninchi D. Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys 2000; 47:305-12. [PMID: 10802353 DOI: 10.1016/s0360-3016(99)00553-2] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
PURPOSE To determine the outcome of patients with positive margins after lumpectomy for breast cancer and to address the issue of the relationship between local recurrences and distant metastasis in the absence of chemotherapy. METHODS AND MATERIALS Among 3697 patients with primary breast cancer, we retrospectively analyzed 152 patients who had undergone conservative surgery with axillary dissection, had infiltrating carcinomas with positive margins, were node-negative, and received radiotherapy without chemotherapy. One-third received hormonal therapy. Endpoints were local failure and distant metastasis. Median follow-up was 72 months. RESULTS Five- and 10-year recurrence-free survival were 0.80 and 0.71 respectively for local recurrences, and 0.85 and 0.73 respectively for metastasis. Infiltrating carcinoma on the margins was associated with early local relapse as opposed to intraductal carcinoma. Local and distant recurrences had similar patterns of yearly-event probabilities. Hazard of relapsing from metastasis was 2.5 times higher after a local recurrence. In the multivariate analysis, negative estrogen receptors (ER-)(p = 0.0012), histologic multifocality (p = 0.0028), and no hormonal therapy (p = 0.017) predicted local relapses, while ER- (p = 0.004) and pathologic grade (p = 0.009) predicted metastasis. Hormonal therapy did not prevent early local recurrences. CONCLUSION In this population, reexcision is advisable for local purposes and because the data support the hypothesis that local and distant recurrences are tightly connected.
Collapse
MESH Headings
- Adult
- Analysis of Variance
- Axilla
- Breast Neoplasms/radiotherapy
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/radiotherapy
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Lobular/radiotherapy
- Carcinoma, Lobular/secondary
- Carcinoma, Lobular/surgery
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymph Nodes
- Neoplasm Recurrence, Local
- Neoplasm, Residual
Collapse
Affiliation(s)
- D Cowen
- Department of Radiation Oncology, Institut Paoli-Calmettes Cancer Center and Reseau Convergence Cancer (R2C), Marseille, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Genre D, Viens P, Gravis G, Bertucci F, Cowen D, Novakovitch G, Derméche S, Chabannon C, Oziel-Taieb S, Camerlo J, Houvenaeghel G, Jacquemier J, Maraninchi D. Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study. Anticancer Res 2000; 20:2033-40. [PMID: 10928147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
We evaluated the feasibility of administering, in an out-patient setting, a sequential high dose alkylating regimen with hematopoietic growth factor (HGF) and stem cell support to patients with advanced breast cancer. Peripheral blood stem cells (PBSC) were previously collected after chemotherapy and HGF. Two consecutive cycles of alkylating agents were planned: Thiotepa (T) then, 15 days later, BCNU (B). Three dose levels of each agent were administered in cohorts of consecutive patients: 400, 500 and 600 mg/m2 respectively. HGF and reinfusion of PBSC followed both cycles. Toxicity and response were evaluated according to the WHO recommendations. From April 1996 to August 1988, 30 women were enrolled: 8 in the first, 12 in the second and 10 in the third dose level. In all cases, B was administered after T with a median delay of 25 days because of grade 3/4 hematological toxicity. 4 patients did not receive B because of previous lung radiotherapy, persistent tricytopenia or insufficient PBSC collection. 19 patients with measurable lesions were considered for response. The objective response rate was 48% (11% CR, 37% PR). We recommended T and B at a dose of 600 mg/m2 to conduct a phase II study in metastatic breast cancer and even to administer B before T.
Collapse
Affiliation(s)
- D Genre
- Institut Paoli-Calmettes, Marseilles, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Protière C, Viens P, Genre D, Cowen D, Camerlo J, Gravis G, Alzieu C, Bertucci F, Resbeut M, Maraninchi D, Moatti JP. Patient participation in medical decision-making: a French study in adjuvant radio-chemotherapy for early breast cancer. Ann Oncol 2000; 11:39-45. [PMID: 10690385 DOI: 10.1023/a:1008390027720] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Shared decision-making is increasingly advocated as an ideal model. However, very few studies have tested the feasibility of giving patients the opportunity to participate in the choice of treatment. PATIENTS AND METHODS Women, with non-metastatic breast cancer, eligible for non-intensified adjuvant chemotherapy attending our hospital were proposed two administrations of chemotherapy and radiotherapy: a sequential and a concomitant one. Two patient-questionnaires were used to elicit motivations for their choice and their degree of comfort with the process of decision-making and one questionnaire to test physicians' ability to predict patients' choice. RESULTS Participation rate in the study was 75.3% (n = 64). Majority (64%) of patients chose the concomitant treatment. Multivariate analysis revealed that patients with a lower level of education, who discussed the choice with social circle, and who most feared side-effects were more likely to choose the sequential treatment. Physicians were able to predict patients' choice in 66% of cases. 89% of patients declared that they were fully satisfied with having participated in the choice of treatment and 79% supported shared decision-making. CONCLUSIONS Results are in favour of promoting active participation of cancer-patients in medical decision-making. The adequate degree of such participation remains however to be elicited and tested for therapeutic choices implying more difficult trade-offs between quantity and quality of life.
Collapse
Affiliation(s)
- C Protière
- Institut Paoli-Calmettes, Regional Centre for Cancer Care, Marseilles, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Besson D, Cowen D, Selen M, Wiebusch C. Neutrinos. Proc Natl Acad Sci U S A 1999; 96:14201-2. [PMID: 10588680 PMCID: PMC33947 DOI: 10.1073/pnas.96.25.14201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Neutrinos represent a new "window" to the Universe, spanning a large range of energy. We discuss the science of neutrino astrophysics and focus on two energy regimes. At "lower" energies ( approximately 1 MeV), studies of neutrinos born inside the sun, or produced in interactions of cosmic rays with the atmosphere, have allowed the first incontrovertible evidence that neutrinos have mass. At energies typically one thousand to one million times higher, sources further than the sun (both within the Milky Way and beyond) are expected to produce a flux of particles that can be detected only through neutrinos.
Collapse
Affiliation(s)
- D Besson
- Department of Physics, University of Kansas, Lawrence, KS 66045, USA
| | | | | | | |
Collapse
|
42
|
Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999; 41:166-72. [PMID: 10517874 DOI: 10.1002/(sici)1097-0045(19991101)41:3<166::aid-pros3>3.0.co;2-e] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Our purpose was to evaluate the relationship of Ki-67 labeling index (Ki67-LI) to deoxyribonucleic acid (DNA) ploidy, S phase fraction (SPF), other clinical prognostic factors, and clinical outcome for patients with prostate cancer treated by external beam radiotherapy. METHODS Tissue was retrieved from 42 patients who underwent transurethral resection of the prostate before treatment with external beam radiotherapy between 1987-1993. DNA histogram profiles were classified as diploid (diploid + near-diploid) and nondiploid (tetraploid + aneuploid). Immunohistochemical staining of Ki-67 by the MIB-1 monoclonal antibody was used to calculate Ki67-LI. Median patient follow-up was 62 months. Treatment failure was defined as two consecutive rises in serum prostate-specific antigen (PSA) or clinical evidence of disease recurrence. RESULTS The mean and median Ki67-LIs were 3.1 and 2.4, respectively (range, 0-12.4). Mean Ki67-LI values were significantly associated with higher stage, Gleason score, and pretreatment PSA. Nondiploid tumors had significantly higher Ki67-LIs, as did patients who failed radiotherapy over the follow-up period. SPF was not significantly correlated with Ki67-LI. As a categorical variable, the most significant relationships were seen when Ki67-LI was subdivided into thirds around the median (Ki67-LI </=1.5%, Ki67-LI >1.5-3.5%, and Ki67-LI >3.5%). This trichotomous variable correlated significantly with pretreatment PSA (P = 0.0008), tumor stage (P = 0.016), Gleason score (P = 0.024), and treatment failure (P = 0.0015), but not with DNA-ploidy (P = 0.15). In actuarial univariate analyses, Ki67-LI appeared to be a more significant predictor of patient outcome (P = 0.003) than DNA-ploidy (P = 0.035). CONCLUSIONS The Ki67-LI correlated with known prognostic factors such as pretreatment PSA, tumor stage, and Gleason score, and was also weakly related to DNA-ploidy. In comparison to DNA-ploidy, Ki67 LI seems to be a better correlate of treatment outcome.
Collapse
Affiliation(s)
- V S Khoo
- Department of Clinical Radiation Oncology, U.T. M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Cowen D, Fermé C. Radiothérapie des formes étendues de la maladie de Hodgkin: vers une limitation des indications ? Cancer Radiother 1999. [DOI: 10.1016/s1278-3218(00)88240-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Genre D, Oziel-Taïeb S, Gravis G, Cowen D, Viret F, Goncalvez A, Maraninchi D, Viens P. Evaluation of the efficacy of granisétron in patients receiving a high-dose sequential chemotherapy for breast cancer. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81960-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85:2460-8. [PMID: 10357419 DOI: 10.1002/(sici)1097-0142(19990601)85:11<2460::aid-cncr23>3.0.co;2-n] [Citation(s) in RCA: 251] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND The current study was undertaken to evaluate the incidence and predictors of late toxicity in patients with localized prostate carcinoma treated with high dose three-dimensional conformal radiotherapy (3D-CRT). METHODS A total of 743 patients with prostate carcinoma classified as T1c-T3 were treated with 3D-CRT that targeted the prostate and seminal vesicles. A minimum tumor dose of 64.8 gray (Gy) was given to 96 patients (13%), 70.2 Gy to 266 patients (365), 75.6 Gy to 320 patients (43%), and 81.0 Gy to 61 patients (8%). The median follow-up time was 42 months (range, 18-109 months). Late toxicity was graded according to the Radiation Therapy Oncology Group morbidity scoring scale. RESULTS Late gastrointestinal (GI) and urinary (GU) toxicities were absent or minimal (Grade 0 or 1) in 90% of patients. The 5-year actuarial likelihood of the development of Grade 2 and 3 late GI toxicities was 11% and 0.75%, respectively. A multivariate analysis identified doses > or =75.6 Gy (P<0.001), history of diabetes mellitus (P = 0.01), and the presence of acute GI symptoms during treatment (P = 0.02) as independent predictors of Grade > or =2 late GI toxicity. The 5-year actuarial likelihood of the development of Grade 2 and 3 late GU toxicities was 10% and 3%, respectively. Doses > or =75.6 Gy (P = 0.008) and acute GU symptoms (P<0.001) were independent predictors of Grade > or =2 late GU toxicity. Among 544 patients who were potent before treatment (73% of all patients), 211 (39%) became impotent after 3D-CRT. The 5-year actuarial risk of potency loss was 60%. Doses > or =75.6 Gy (P<0.001) and the use of neoadjuvant androgen deprivation (P = 0.01) were independent predictors of posttreatment erectile dysfunction. CONCLUSIONS The incidence of severe late complications after high dose 3D-CRT was minimal. Radiation doses > or =75.6 Gy and the presence of acute treatment-related symptoms during 3D-CRT correlated with a higher incidence of Grade > or =2 late GI and GU toxicities. In addition to higher doses, the use of androgen deprivation therapy increased the likelihood of permanent impotence in these patients. Intensity-modulated radiotherapy, which makes it possible to enhance the conformality of the dose distribution, has recently been implemented in an attempt to reduce the incidence of moderate grade toxicities in patients receiving high dose 3D-CRT.
Collapse
Affiliation(s)
- M J Zelefsky
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
The use of radiotherapy in advanced stages of Hodgkin's disease remains controversial. The rationale for its use is based on efficacy at all stages of the disease as well as in patients with recurrent disease, but also on the topography of the recurrences after exclusive chemotherapy (which occur at non irradiated sites in 75% of cases), and on its ability to improve relapse rates as shown in many randomized trials. Unfortunately, this improvement does not translate into higher survival rates because of the increased late morbidity and an inadequate selection of patients who might benefit from irradiation. The benefits of radiotherapy are probably the highest in stage III rather than IV, in patients with scleronodular disease, and in those with mediastinal involvement experiencing a complete response to radiotherapy. A better survival should be observed with the shift towards a decrease of the doses delivered, an improvement of the quality of the irradiation, and a better definition of the volumes to be treated in association with the use of optimal chemotherapies.
Collapse
Affiliation(s)
- D Cowen
- Département de radiothérapie, institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
47
|
Mathoulin-Portier MP, Meynard P, Charton-Bain MC, Escoute M, Bardou VJ, Puig B, Viens P, Cowen D, Houvenaeghel G, Hassoun J, Jacquemier J. Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy. Anticancer Res 1999; 19:843-7. [PMID: 10216503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
BACKGROUND The prognostic value of peritumoral vascular invasion (PVI) in node negative breast cancer (N-) is a controversial issue. Considerable debate has focused on how PVI should be defined, and the techniques used to detect them have differed considerably from one study to another. MATERIAL AND METHODS In our study, 167 cases of N- breast cancers were reviewed, with a view to determining whether or not PVI, as defined in the recently published European recommendations, were present. RESULTS Based on the results of the subsequent statistical study, the presence of PVI was not found to constitute a reliable prognostic index to the outcome of N- breast cancer. CONCLUSION Referring each case to the data available in the literature, the difficulties encountered when searching for PVI of this kind are described, the results of various studies on the topic are reviewed and whether it is worth pursuing studies along these lines is discussed.
Collapse
|
48
|
Cowen D, Houvenaeghel G, Jacquemier J, Resbeut M, Largillier R, Bardou VJ, Viens P, Maraninchi D. [Local recurrences after conservative treatment of breast cancer: risk factors and influence on survival]. Cancer Radiother 1998; 2:460-8. [PMID: 9868388 DOI: 10.1016/s1278-3218(98)80033-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIMS OF THE STUDY To determine the risk factors for local and distant failure in node-negative breast cancer treated with breast-conservative surgery and radiotherapy and to determine the relationship between these two events. MATERIAL AND METHODS We retrospectively selected 908 patients who received conservative surgery and radiotherapy but no chemotherapy between 1980 and 1995, for a node-negative breast cancer. Patients were divided in two groups according to the status of the margins of resection. All pathology specimens were reviewed. RESULTS In case of negative margins, the risk factors for local recurrences picked up by the Cox model were histologic multifocality (P = 0.0076), peritumoral vessel invasion (P = 0.021) and age < or = 40 years (P = 0.024), and in case of involved margins, negative oestrogen receptors (P = 0.0012), histologic multifocality (P = 0.0028), and absence of hormonal therapy (P = 0.017). The 10-year local recurrence rate was 18% in case of negative margins and 29% in case of involved margins, although in the latter case patients received high-dose adjuvant radiotherapy. Accordingly, the 10-year distant failure rates were 16% and 27%, respectively. Many arguments suggest that local and distant failures are closely related. CONCLUSION Patients with histologic multifocality or positive margins are at high risk of local failure and then of distant failure, and require a more aggressive initial treatment.
Collapse
Affiliation(s)
- D Cowen
- Département de radiothérapie, institut Paoli-Calmettes, Marseille, France
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Cowen D, Hannoun-Levi JM, Resbeut M, Alzieu C. Natural history and treatment of malignant thymoma. Oncology (Williston Park) 1998; 12:1001-5; discussion 1006. [PMID: 9684271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Thymomas are rare, slow-growing neoplasms that are considered to be malignant because of their potential invasiveness. The most widely used staging system is that of Masaoka and colleagues, which takes into account the extent of clinical and histopathologically determined disease involvement. However, recent data suggest that the staging system of the French Study Group on Thymic Tumors (GETT system), which is based on the surgical and pathologic features of the tumor, may be superior to the Masaoka system. Total resection followed by radiation therapy is the treatment of choice for all thymomas, except stage IA tumors, which can be treated with surgery alone. Chemotherapy can improve the outcome of invasive Masaoka stage III and IV thymomas or recurrent thymomas. Only platinum-containing regimens show consistent efficacy.
Collapse
Affiliation(s)
- D Cowen
- Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France
| | | | | | | |
Collapse
|
50
|
Cowen D, Gonzague-Casabianca L, Brenot-Rossi I, Viens P, Mace L, Hannoun-Levi JM, Alzieu C, Resbeut M. Thallium-201 perfusion scintigraphy in the evaluation of late myocardial damage in left-side breast cancer treated with adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41:809-15. [PMID: 9652842 DOI: 10.1016/s0360-3016(98)00019-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
PURPOSE To evaluate late myocardial damage after adjuvant radiotherapy using a mixed-beam (photons plus electrons) technique to treat the internal mammary lymph nodes in left-side breast cancer. METHODS AND MATERIALS A bicycle ergometer stress test coupled with thallium-201 perfusion scintigraphy and analysis by single-photon computed tomography (CT) was performed on 19 patients treated with left-side breast/chest wall and internal mammary radiation for breast cancer between 1987 and 1993. To be sure that we would evaluate late toxicity caused by the irradiation, patients had to fulfill the following eligibility criteria: left-side breast cancer, treatment between 1987 and 1993 and no recurrence during follow-up, age < or = 75 years, no known risk for coronary artery disease, no previous chemotherapy, internal mammary field treated with an association of photons and electrons, and CT scan-based treatment planning. RESULTS Median age at scintigraphy was 59 years. Two patients did not reach optimal exercise level and were not evaluable. Among the 17 evaluable patients representing 91.6 patient years of follow-up, there were no perfusion defects by visual or quantitative analysis. CONCLUSION The mixed-beam technique seemed to spare the heart from harmful irradiation and to protect the myocardium. Results need to be confirmed on the long-term use of this technique.
Collapse
Affiliation(s)
- D Cowen
- Department of Radiation Oncology, Institut Paoli-Calmettes Cancer Center, Marseille, France
| | | | | | | | | | | | | | | |
Collapse
|